Deal Watch: Neos Says ‘Thanks, No Thanks’ To Repeated PDL Offer
Executive Summary
Daiichi teams with Glycotope on an antibody-drug conjugate for cancer, while Alector will partner with AbbVie to research antibody targets for Alzheimer’s disease.
You may also be interested in...
Evofem Plans 2019 Refiling For Amphora Based On New 86% Contraception Efficacy
Evofem intends to refile the NDA for its non-hormonal contraceptive Amphora during the second quarter of 2019, after the Phase III AMPOWER study showed 86% efficacy for typical use and 98.7% efficacy when the gel was used as directed.
Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.
Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US
Public Company Edition: Kiniksa, Scholar Rock and Iterum launch the most recent US IPOs and at least five more drug developers join the queue. Also, Polyphor go public in Switzerland, Valeant and Ligand sell notes, and MyoKardia led recent follow-on offerings.